Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

This study is testing Claudin18.2 CAR-T cell therapy — immune cells engineered to target a protein called Claudin 18.2 found on gastric and pancreatic cancer cells — in people with advanced stomach or pancreatic cancer. **You may be eligible if...** - You are between 18 and 75 years old with confirmed advanced gastric (stomach) or pancreatic cancer that cannot be removed surgically - Your tumor tissue shows moderate to high levels of Claudin 18.2 protein by immunohistochemistry - You have already received first-line and second-line standard treatments - Your cancer is stage III or IV and is not eligible for curative surgery, chemotherapy, or radiation - Your general health score is 0–2 and expected survival is more than 3 months **You may NOT be eligible if...** - Your tumor does not express Claudin 18.2 - You have not had prior standard treatments - Your blood counts or organ function fall below required minimums - You are allergic to any component of the cell product - You have received antibody therapy in the 2 weeks before treatment Talk to your doctor to see if this trial is right for you.